Key result
CYP2C19*2 or *3 alleles strongly linked to short-term angina relapse after ACS stenting.
Why the study?
The study aimed to identify and rank factors predisposing to angina relapse in Buryat patients who underwent percutaneous intervention for acute coronary syndrome.
Observational (n=142)
Carriage of CYP2C19 loss-of-function alleles, concomitant omeprazole use, male sex, and elevated blood glucose are independent predictors of short-term angina relapse in Buryat patients after ACS stenting on clopidogrel.
Answers are grounded in this paper and cite their sources.
May guide PPI selection and monitoring in clopidogrel-treated post-stent patients; hypothesis-generating for pharmacogenetics in Buryat cohorts pending validation.
Aim. To identify and rank factors predisposing to angina relapse in Buryat patients who underwent percutaneous intervention for acute coronary syndrome. Material and methods. The study included 142 Buryat patients who underwent coronary stenting for acute coronary syndrome. All patients received clopidogrel. The CYP2C19*2 and CYP2C19*3 alleles were determined. Efficacy endpoints were assessed according to the Academic Research Consortium-2 criteria. Laboratory parameters and concomitant omeprazole therapy were assessed. Results. This study examined in detail a group of patients with short-term angina relapse without formal signs of unstable angina. A logistic regression model was obtained that makes it possible to identify and rank independent risk factors for recurrent angina in Buryat patients. Risk factors were ranked as follows: carriage of CYP2C19*2 and/or CYP2C19*3 alleles (coefficient b1=3,489, 95% confidence interval (CI) (3,096-346,213)), treatment with omeprazole (b2=2,816, 95% CI (2,745-101,616)), male sex (b3=2,749, 95% CI (1,425-163,458)) and blood glucose level (b4=0,354, 95% CI (1,141-1,779)). Conclusion. Thus, angina pain relapse in Buryat patients is facilitated by signs significant for recurrent myocardial infarction. This study suggests that patients with recurrent angina pain without electrocardiographic deterioration and biomarker elevation may require more careful personalization of therapy.
No takes yet. Share an insight, caveat, or question.
Zelenskaya et al. (2023) conducted an observational in acute coronary syndrome (n=142). CYP2C19*2 and/or CYP2C19*3 alleles was evaluated on short-term angina relapse (coefficient 3.489, 95% CI 3.096-346.213). Carriage of CYP2C19*2 or *3 alleles was the strongest risk factor for short-term angina relapse in Buryat patients post-stenting for ACS.
Synapse has enriched 10 related papers. Consider them for comparative context: